Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Efficacy and Safety of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anaemias

Next Previous
Trial Profile

The Efficacy and Safety of Ferriprox for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anaemias

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferiprone (Primary) ; Deferoxamine
  • Indications Iron overload
  • Focus Therapeutic Use
  • Acronyms FIRST
  • Sponsors ApoPharma

    • Most Recent Events

    • 14 Dec 2023 Results of Pediatric subgroup and post hoc analysis comparing efficacy and safety of deferiprone versus deferoxamine in children with SCD, published in the Pediatric Blood and Cancer
    • 14 Dec 2021 Results of subgroup analysis (n=228) of the FIRST (NCT02041299) study to assess whether the efficacy and safety of deferiprone are comparable to deferiprone in children with sickle cell disease, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
    • 16 Jul 2021 Status changed from recruiting to discontinued.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top